| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 61 | 2026 | 1041 | 9.300 |
Why?
|
| Neurovascular Coupling | 25 | 2024 | 154 | 7.220 |
Why?
|
| Cognitive Dysfunction | 30 | 2026 | 271 | 5.940 |
Why?
|
| Endothelium, Vascular | 18 | 2026 | 347 | 4.030 |
Why?
|
| Cerebrovascular Circulation | 26 | 2025 | 227 | 3.450 |
Why?
|
| Mitochondria | 12 | 2026 | 419 | 2.680 |
Why?
|
| Cognition | 14 | 2025 | 331 | 2.540 |
Why?
|
| Hypertension | 13 | 2023 | 309 | 2.430 |
Why?
|
| Dementia, Vascular | 7 | 2026 | 57 | 2.380 |
Why?
|
| Oxidative Stress | 25 | 2026 | 692 | 2.350 |
Why?
|
| Animals | 78 | 2026 | 10806 | 2.170 |
Why?
|
| Cognition Disorders | 7 | 2020 | 186 | 2.080 |
Why?
|
| Insulin-Like Growth Factor I | 9 | 2026 | 311 | 2.000 |
Why?
|
| Mice | 51 | 2026 | 4870 | 1.930 |
Why?
|
| Mice, Inbred C57BL | 41 | 2026 | 1684 | 1.930 |
Why?
|
| Endothelial Cells | 9 | 2026 | 377 | 1.730 |
Why?
|
| Brain | 25 | 2025 | 774 | 1.700 |
Why?
|
| Alzheimer Disease | 8 | 2023 | 225 | 1.660 |
Why?
|
| Cerebral Hemorrhage | 7 | 2023 | 94 | 1.600 |
Why?
|
| Astrocytes | 6 | 2021 | 80 | 1.600 |
Why?
|
| Rejuvenation | 6 | 2026 | 43 | 1.480 |
Why?
|
| Aorta | 3 | 2024 | 124 | 1.390 |
Why?
|
| Microcirculation | 12 | 2020 | 113 | 1.380 |
Why?
|
| Transcriptome | 6 | 2026 | 244 | 1.320 |
Why?
|
| Hyperemia | 5 | 2025 | 40 | 1.310 |
Why?
|
| Vasodilation | 5 | 2024 | 119 | 1.290 |
Why?
|
| Blood-Brain Barrier | 10 | 2026 | 108 | 1.220 |
Why?
|
| Fasting | 3 | 2026 | 91 | 1.150 |
Why?
|
| Gait | 6 | 2021 | 61 | 1.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2023 | 68 | 1.050 |
Why?
|
| Inflammation | 7 | 2026 | 672 | 1.050 |
Why?
|
| Cellular Senescence | 11 | 2025 | 149 | 1.040 |
Why?
|
| Nicotinamide Mononucleotide | 4 | 2020 | 23 | 1.020 |
Why?
|
| Reactive Oxygen Species | 8 | 2024 | 303 | 1.010 |
Why?
|
| Cerebrovascular Disorders | 5 | 2020 | 49 | 1.000 |
Why?
|
| Lipoproteins, LDL | 2 | 2026 | 42 | 0.970 |
Why?
|
| Male | 53 | 2026 | 14126 | 0.970 |
Why?
|
| NF-E2-Related Factor 2 | 6 | 2024 | 130 | 0.960 |
Why?
|
| Dietary Supplements | 7 | 2025 | 274 | 0.940 |
Why?
|
| Microvessels | 9 | 2026 | 99 | 0.930 |
Why?
|
| Maze Learning | 7 | 2019 | 78 | 0.910 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2026 | 51 | 0.900 |
Why?
|
| Humans | 60 | 2026 | 29211 | 0.890 |
Why?
|
| Gene Expression Regulation | 6 | 2026 | 646 | 0.850 |
Why?
|
| Longevity | 3 | 2024 | 141 | 0.810 |
Why?
|
| Age Factors | 13 | 2024 | 740 | 0.800 |
Why?
|
| Disease Models, Animal | 22 | 2023 | 1524 | 0.790 |
Why?
|
| Obesity | 6 | 2024 | 705 | 0.780 |
Why?
|
| Hippocampus | 6 | 2019 | 198 | 0.770 |
Why?
|
| Antioxidants | 5 | 2023 | 228 | 0.760 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2020 | 38 | 0.730 |
Why?
|
| Aniline Compounds | 1 | 2021 | 23 | 0.690 |
Why?
|
| Cognitive Aging | 3 | 2020 | 22 | 0.680 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2021 | 54 | 0.680 |
Why?
|
| Sulfonamides | 1 | 2021 | 73 | 0.660 |
Why?
|
| Microvascular Rarefaction | 2 | 2021 | 13 | 0.660 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2020 | 23 | 0.650 |
Why?
|
| Geriatrics | 3 | 2020 | 47 | 0.630 |
Why?
|
| Phenanthrenes | 1 | 2019 | 10 | 0.610 |
Why?
|
| Catalase | 1 | 2019 | 52 | 0.600 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2023 | 847 | 0.590 |
Why?
|
| Angiotensin II | 6 | 2021 | 55 | 0.580 |
Why?
|
| Parabiosis | 3 | 2026 | 27 | 0.560 |
Why?
|
| MicroRNAs | 3 | 2019 | 305 | 0.560 |
Why?
|
| NG-Nitroarginine Methyl Ester | 4 | 2019 | 31 | 0.530 |
Why?
|
| Extracellular Matrix | 2 | 2017 | 117 | 0.500 |
Why?
|
| Aged | 21 | 2025 | 5648 | 0.500 |
Why?
|
| Neocortex | 1 | 2016 | 9 | 0.490 |
Why?
|
| NAD | 3 | 2025 | 104 | 0.490 |
Why?
|
| Mice, Transgenic | 5 | 2021 | 514 | 0.450 |
Why?
|
| Peptides | 1 | 2018 | 297 | 0.450 |
Why?
|
| Dementia | 4 | 2023 | 98 | 0.430 |
Why?
|
| Phenotype | 5 | 2021 | 689 | 0.420 |
Why?
|
| Gene Expression Profiling | 6 | 2026 | 479 | 0.420 |
Why?
|
| Vascular Diseases | 3 | 2019 | 68 | 0.410 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2024 | 75 | 0.400 |
Why?
|
| Neovascularization, Physiologic | 5 | 2019 | 127 | 0.390 |
Why?
|
| Pandemics | 4 | 2023 | 210 | 0.380 |
Why?
|
| Signal Transduction | 10 | 2026 | 1502 | 0.370 |
Why?
|
| White Matter | 2 | 2023 | 90 | 0.350 |
Why?
|
| Peripheral Arterial Disease | 2 | 2025 | 144 | 0.340 |
Why?
|
| Mice, Knockout | 7 | 2019 | 881 | 0.340 |
Why?
|
| Nitric Oxide | 4 | 2019 | 153 | 0.330 |
Why?
|
| Biomarkers | 6 | 2024 | 790 | 0.330 |
Why?
|
| Diet, High-Fat | 4 | 2024 | 144 | 0.310 |
Why?
|
| Stilbenes | 3 | 2016 | 91 | 0.310 |
Why?
|
| Cerebral Cortex | 3 | 2021 | 136 | 0.310 |
Why?
|
| Oxidation-Reduction | 4 | 2026 | 381 | 0.300 |
Why?
|
| Middle Cerebral Artery | 5 | 2021 | 56 | 0.300 |
Why?
|
| Neuronal Plasticity | 2 | 2019 | 51 | 0.280 |
Why?
|
| Energy Metabolism | 3 | 2026 | 217 | 0.270 |
Why?
|
| Enzyme Inhibitors | 3 | 2019 | 252 | 0.270 |
Why?
|
| Lameness, Animal | 2 | 2017 | 8 | 0.260 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 2 | 2019 | 7 | 0.260 |
Why?
|
| Hemodynamics | 4 | 2021 | 221 | 0.260 |
Why?
|
| Cerebral Arteries | 2 | 2019 | 34 | 0.250 |
Why?
|
| Indomethacin | 2 | 2017 | 15 | 0.250 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2017 | 25 | 0.250 |
Why?
|
| Annexin A2 | 1 | 2026 | 13 | 0.240 |
Why?
|
| Adipose Tissue, Beige | 1 | 2026 | 8 | 0.240 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2026 | 35 | 0.240 |
Why?
|
| Adipose Tissue, White | 1 | 2026 | 24 | 0.230 |
Why?
|
| PPAR alpha | 1 | 2026 | 44 | 0.230 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2025 | 9 | 0.230 |
Why?
|
| Gene Expression | 2 | 2018 | 418 | 0.230 |
Why?
|
| Niacinamide | 1 | 2025 | 32 | 0.220 |
Why?
|
| Female | 19 | 2025 | 15825 | 0.220 |
Why?
|
| Disease Progression | 3 | 2023 | 483 | 0.220 |
Why?
|
| Sleep Deprivation | 2 | 2021 | 28 | 0.220 |
Why?
|
| Time Factors | 3 | 2024 | 1619 | 0.210 |
Why?
|
| Adipose Tissue | 1 | 2026 | 197 | 0.210 |
Why?
|
| Prebiotics | 1 | 2024 | 3 | 0.210 |
Why?
|
| Heart | 1 | 2025 | 232 | 0.210 |
Why?
|
| Aldehydes | 1 | 2024 | 55 | 0.210 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 18 | 0.200 |
Why?
|
| Zoonoses | 2 | 2021 | 13 | 0.200 |
Why?
|
| Quality of Life | 6 | 2023 | 523 | 0.200 |
Why?
|
| Vitamins | 1 | 2023 | 23 | 0.200 |
Why?
|
| Probiotics | 1 | 2024 | 20 | 0.200 |
Why?
|
| Diet, Mediterranean | 1 | 2023 | 2 | 0.200 |
Why?
|
| Hyperhomocysteinemia | 1 | 2023 | 29 | 0.200 |
Why?
|
| Electroretinography | 1 | 2024 | 180 | 0.200 |
Why?
|
| Random Allocation | 3 | 2019 | 152 | 0.200 |
Why?
|
| Vitamin B Complex | 1 | 2023 | 4 | 0.200 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2023 | 14 | 0.190 |
Why?
|
| Memory, Short-Term | 2 | 2021 | 64 | 0.190 |
Why?
|
| Risk Factors | 5 | 2020 | 2144 | 0.190 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2022 | 40 | 0.180 |
Why?
|
| Telerehabilitation | 1 | 2021 | 1 | 0.180 |
Why?
|
| Blood Pressure | 4 | 2015 | 358 | 0.170 |
Why?
|
| Plaque, Amyloid | 1 | 2021 | 12 | 0.170 |
Why?
|
| bcl-X Protein | 1 | 2021 | 35 | 0.170 |
Why?
|
| Noninvasive Ventilation | 1 | 2021 | 2 | 0.170 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2021 | 34 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 68 | 0.170 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2021 | 8 | 0.170 |
Why?
|
| Intravital Microscopy | 1 | 2021 | 10 | 0.170 |
Why?
|
| Motor Cortex | 1 | 2021 | 48 | 0.170 |
Why?
|
| Neurosciences | 1 | 2020 | 10 | 0.160 |
Why?
|
| Behavior, Animal | 2 | 2019 | 108 | 0.160 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2020 | 6 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 6 | 0.160 |
Why?
|
| Retina | 1 | 2024 | 446 | 0.160 |
Why?
|
| Capillary Permeability | 1 | 2021 | 56 | 0.160 |
Why?
|
| Calcium Signaling | 2 | 2020 | 72 | 0.160 |
Why?
|
| Matrix Metalloproteinases | 2 | 2017 | 31 | 0.160 |
Why?
|
| Models, Animal | 1 | 2020 | 130 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 346 | 0.160 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 526 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 40 | 0.160 |
Why?
|
| Homeostasis | 3 | 2016 | 122 | 0.150 |
Why?
|
| Phthalazines | 1 | 2020 | 25 | 0.150 |
Why?
|
| Pancreatitis | 1 | 2020 | 36 | 0.150 |
Why?
|
| Tomography, Optical Coherence | 1 | 2021 | 103 | 0.150 |
Why?
|
| Rest | 1 | 2020 | 96 | 0.150 |
Why?
|
| Neuroprotective Agents | 2 | 2019 | 53 | 0.150 |
Why?
|
| Wet Macular Degeneration | 1 | 2019 | 9 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 58 | 0.150 |
Why?
|
| Sirtuin 1 | 1 | 2020 | 41 | 0.150 |
Why?
|
| Piperazines | 1 | 2020 | 50 | 0.150 |
Why?
|
| Choroid | 1 | 2019 | 21 | 0.150 |
Why?
|
| Inflammation Mediators | 2 | 2018 | 169 | 0.150 |
Why?
|
| Blood Vessels | 1 | 2020 | 58 | 0.150 |
Why?
|
| Caloric Restriction | 2 | 2024 | 74 | 0.150 |
Why?
|
| Lasers | 1 | 2019 | 68 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 55 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 59 | 0.150 |
Why?
|
| Psychomotor Disorders | 1 | 2019 | 5 | 0.150 |
Why?
|
| Retinal Artery | 1 | 2019 | 10 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 49 | 0.150 |
Why?
|
| Chondrogenesis | 1 | 2019 | 29 | 0.150 |
Why?
|
| Oxygen | 1 | 2020 | 238 | 0.150 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2019 | 15 | 0.150 |
Why?
|
| Cartilage, Articular | 1 | 2019 | 44 | 0.150 |
Why?
|
| Photic Stimulation | 1 | 2019 | 71 | 0.150 |
Why?
|
| Cerebral Veins | 1 | 2019 | 11 | 0.150 |
Why?
|
| Eicosanoids | 1 | 2019 | 10 | 0.150 |
Why?
|
| Retinal Vessels | 1 | 2019 | 75 | 0.150 |
Why?
|
| Visual Perception | 1 | 2019 | 45 | 0.150 |
Why?
|
| Middle Aged | 10 | 2025 | 7495 | 0.150 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2019 | 48 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2016 | 55 | 0.140 |
Why?
|
| Brain Concussion | 1 | 2019 | 53 | 0.140 |
Why?
|
| Down-Regulation | 2 | 2016 | 203 | 0.140 |
Why?
|
| Liver | 2 | 2026 | 497 | 0.140 |
Why?
|
| Oligopeptides | 1 | 2019 | 97 | 0.140 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 41 | 0.140 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 64 | 0.140 |
Why?
|
| Regional Blood Flow | 1 | 2019 | 168 | 0.140 |
Why?
|
| Memory | 2 | 2017 | 76 | 0.140 |
Why?
|
| Valsalva Maneuver | 1 | 2018 | 8 | 0.140 |
Why?
|
| Liposomes | 1 | 2019 | 145 | 0.140 |
Why?
|
| Amyloidogenic Proteins | 1 | 2018 | 7 | 0.140 |
Why?
|
| Mice, Inbred ICR | 1 | 2018 | 26 | 0.140 |
Why?
|
| Hand Strength | 2 | 2015 | 39 | 0.140 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 198 | 0.140 |
Why?
|
| Telemedicine | 1 | 2021 | 228 | 0.140 |
Why?
|
| Arteries | 1 | 2018 | 66 | 0.140 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2015 | 35 | 0.130 |
Why?
|
| DNA Damage | 1 | 2019 | 153 | 0.130 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2017 | 9 | 0.130 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 406 | 0.130 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2017 | 10 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2016 | 669 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 236 | 0.130 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2017 | 31 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2016 | 392 | 0.120 |
Why?
|
| Psychomotor Performance | 1 | 2017 | 73 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 148 | 0.120 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 2 | 2013 | 16 | 0.120 |
Why?
|
| Dietary Sucrose | 1 | 2016 | 7 | 0.120 |
Why?
|
| Neoplasms | 1 | 2025 | 888 | 0.120 |
Why?
|
| Adaptation, Physiological | 2 | 2015 | 177 | 0.120 |
Why?
|
| Rats | 5 | 2019 | 1595 | 0.120 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2015 | 4 | 0.120 |
Why?
|
| Arterioles | 3 | 2022 | 61 | 0.120 |
Why?
|
| Somatosensory Cortex | 1 | 2015 | 17 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2015 | 15 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 1013 | 0.110 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2015 | 14 | 0.110 |
Why?
|
| Postural Balance | 1 | 2015 | 44 | 0.110 |
Why?
|
| Pulsatile Flow | 1 | 2015 | 9 | 0.110 |
Why?
|
| Cell Communication | 1 | 2015 | 70 | 0.110 |
Why?
|
| Vasoconstriction | 1 | 2015 | 45 | 0.110 |
Why?
|
| Intracranial Hemorrhages | 1 | 2015 | 32 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 2070 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2023 | 1288 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 384 | 0.100 |
Why?
|
| Cerebrum | 1 | 2013 | 14 | 0.100 |
Why?
|
| Minerals | 2 | 2023 | 15 | 0.100 |
Why?
|
| Vitamin K | 2 | 2023 | 39 | 0.100 |
Why?
|
| Vitamin A | 2 | 2023 | 32 | 0.100 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 55 | 0.100 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 645 | 0.100 |
Why?
|
| Vasomotor System | 1 | 2013 | 8 | 0.100 |
Why?
|
| Amidines | 1 | 2013 | 8 | 0.100 |
Why?
|
| Rats, Inbred F344 | 3 | 2019 | 174 | 0.090 |
Why?
|
| Oxygen Consumption | 2 | 2026 | 190 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2023 | 431 | 0.080 |
Why?
|
| Neuropsychological Tests | 2 | 2023 | 249 | 0.080 |
Why?
|
| NF-kappa B | 3 | 2016 | 191 | 0.080 |
Why?
|
| Cytokines | 3 | 2019 | 457 | 0.070 |
Why?
|
| Brain Mapping | 2 | 2021 | 208 | 0.070 |
Why?
|
| Adult | 5 | 2021 | 8130 | 0.070 |
Why?
|
| Memory Disorders | 2 | 2019 | 50 | 0.070 |
Why?
|
| Reference Values | 2 | 2019 | 200 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2020 | 632 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 150 | 0.070 |
Why?
|
| Atherosclerosis | 2 | 2019 | 97 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2014 | 1024 | 0.060 |
Why?
|
| Rats, Inbred BN | 2 | 2019 | 72 | 0.060 |
Why?
|
| Rats, Inbred SHR | 2 | 2019 | 13 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2019 | 903 | 0.060 |
Why?
|
| Microglia | 2 | 2019 | 69 | 0.060 |
Why?
|
| Uncoupling Protein 1 | 1 | 2026 | 22 | 0.060 |
Why?
|
| Adipose Tissue, Brown | 1 | 2026 | 22 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2025 | 244 | 0.060 |
Why?
|
| Fibrosis | 1 | 2026 | 145 | 0.060 |
Why?
|
| Pyridinium Compounds | 1 | 2025 | 27 | 0.060 |
Why?
|
| Cell Movement | 2 | 2019 | 378 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2025 | 191 | 0.050 |
Why?
|
| TRPC Cation Channels | 2 | 2014 | 34 | 0.050 |
Why?
|
| Methionine | 1 | 2023 | 38 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2023 | 24 | 0.050 |
Why?
|
| Vegetables | 1 | 2023 | 29 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2025 | 467 | 0.050 |
Why?
|
| Hungary | 1 | 2022 | 5 | 0.050 |
Why?
|
| Young Adult | 2 | 2021 | 2877 | 0.050 |
Why?
|
| Vaccination Coverage | 1 | 2022 | 14 | 0.050 |
Why?
|
| Bronchodilator Agents | 1 | 2022 | 15 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2022 | 45 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 41 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 75 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2023 | 201 | 0.050 |
Why?
|
| Triglycerides | 1 | 2022 | 123 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 94 | 0.040 |
Why?
|
| Muscle, Smooth | 1 | 2022 | 41 | 0.040 |
Why?
|
| Gray Matter | 1 | 2022 | 24 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2022 | 68 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2021 | 11 | 0.040 |
Why?
|
| Mutation | 1 | 2025 | 875 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2022 | 80 | 0.040 |
Why?
|
| Ferrets | 1 | 2021 | 4 | 0.040 |
Why?
|
| Apoptosis | 2 | 2016 | 784 | 0.040 |
Why?
|
| Diet | 1 | 2023 | 243 | 0.040 |
Why?
|
| Cats | 1 | 2021 | 52 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2022 | 82 | 0.040 |
Why?
|
| Control Groups | 1 | 2021 | 1 | 0.040 |
Why?
|
| Reaction Time | 1 | 2021 | 95 | 0.040 |
Why?
|
| Mathematical Computing | 1 | 2001 | 4 | 0.040 |
Why?
|
| Baroreflex | 1 | 2001 | 6 | 0.040 |
Why?
|
| Dyspnea | 1 | 2021 | 26 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2022 | 252 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 198 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 204 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2021 | 80 | 0.040 |
Why?
|
| Dogs | 1 | 2021 | 510 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 222 | 0.040 |
Why?
|
| Ceruletide | 1 | 2020 | 7 | 0.040 |
Why?
|
| Smartphone | 1 | 2021 | 85 | 0.040 |
Why?
|
| Pancreatic Ducts | 1 | 2020 | 10 | 0.040 |
Why?
|
| Public Health | 1 | 2021 | 98 | 0.040 |
Why?
|
| Endothelium | 1 | 2020 | 28 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 484 | 0.040 |
Why?
|
| Preventive Medicine | 1 | 2020 | 14 | 0.040 |
Why?
|
| Spatial Learning | 1 | 2019 | 6 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2020 | 52 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 741 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 74 | 0.040 |
Why?
|
| Sensorimotor Cortex | 1 | 2019 | 7 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 117 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 2 | 2014 | 35 | 0.040 |
Why?
|
| Rodentia | 1 | 2019 | 14 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2019 | 30 | 0.040 |
Why?
|
| Neurons | 1 | 2021 | 297 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2019 | 153 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 128 | 0.040 |
Why?
|
| Exercise | 1 | 2023 | 502 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2019 | 81 | 0.040 |
Why?
|
| Motor Activity | 1 | 2019 | 149 | 0.040 |
Why?
|
| Proteostasis | 1 | 2018 | 10 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2019 | 146 | 0.040 |
Why?
|
| Research | 1 | 2019 | 93 | 0.040 |
Why?
|
| Swimming | 1 | 2018 | 32 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 466 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2018 | 34 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 705 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2019 | 515 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2020 | 272 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 277 | 0.030 |
Why?
|
| DNA | 1 | 2019 | 378 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 554 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 473 | 0.030 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 14 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2018 | 175 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 50 | 0.030 |
Why?
|
| Aneurysm | 1 | 1996 | 26 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 1996 | 37 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 828 | 0.030 |
Why?
|
| Diabetic Retinopathy | 1 | 2017 | 112 | 0.030 |
Why?
|
| Purinergic P2Y Receptor Agonists | 1 | 2015 | 4 | 0.030 |
Why?
|
| Vibrissae | 1 | 2015 | 6 | 0.030 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2015 | 34 | 0.030 |
Why?
|
| Spatial Memory | 1 | 2015 | 16 | 0.030 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2015 | 28 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2015 | 31 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2014 | 9 | 0.030 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2015 | 39 | 0.030 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2014 | 5 | 0.030 |
Why?
|
| Encephalitis | 1 | 2014 | 18 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2017 | 430 | 0.030 |
Why?
|
| Aortic Rupture | 1 | 1994 | 8 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 817 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2014 | 58 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 1994 | 15 | 0.030 |
Why?
|
| Pericytes | 1 | 2014 | 17 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 2014 | 36 | 0.030 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 1994 | 24 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 59 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 139 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 134 | 0.030 |
Why?
|
| United States | 1 | 2020 | 2270 | 0.030 |
Why?
|
| TRPC6 Cation Channel | 1 | 2013 | 6 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2013 | 69 | 0.020 |
Why?
|
| Transfection | 1 | 2014 | 319 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 79 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 179 | 0.020 |
Why?
|
| Rats, Inbred WKY | 1 | 2013 | 15 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 417 | 0.020 |
Why?
|
| Actins | 1 | 2013 | 99 | 0.020 |
Why?
|
| Thrombosis | 1 | 1994 | 155 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 247 | 0.020 |
Why?
|
| Phenylephrine | 1 | 2001 | 14 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2001 | 28 | 0.010 |
Why?
|
| Linear Models | 1 | 2001 | 204 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2001 | 398 | 0.010 |
Why?
|
| Algorithms | 1 | 2001 | 434 | 0.010 |
Why?
|
| Fibromuscular Dysplasia | 1 | 1996 | 1 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 1996 | 7 | 0.010 |
Why?
|
| Carotid Artery, External | 1 | 1996 | 4 | 0.010 |
Why?
|
| Polytetrafluoroethylene | 1 | 1996 | 8 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 1996 | 22 | 0.010 |
Why?
|
| Cranial Nerve Diseases | 1 | 1996 | 10 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 1996 | 24 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1996 | 30 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 1996 | 38 | 0.010 |
Why?
|
| Carotid Artery, Internal | 1 | 1996 | 19 | 0.010 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1996 | 28 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1996 | 28 | 0.010 |
Why?
|
| Anesthesia, General | 1 | 1996 | 30 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1996 | 87 | 0.010 |
Why?
|
| Elective Surgical Procedures | 1 | 1996 | 74 | 0.010 |
Why?
|
| Reoperation | 1 | 1996 | 159 | 0.010 |
Why?
|
| Survival Rate | 1 | 1996 | 433 | 0.010 |
Why?
|
| Aortography | 1 | 1994 | 6 | 0.010 |
Why?
|
| Angiography, Digital Subtraction | 1 | 1994 | 20 | 0.010 |
Why?
|
| Emergencies | 1 | 1994 | 28 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1994 | 23 | 0.010 |
Why?
|
| Child | 1 | 2001 | 2354 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1994 | 212 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1994 | 81 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1996 | 1033 | 0.010 |
Why?
|
| Adolescent | 1 | 2001 | 3255 | 0.010 |
Why?
|
| Incidence | 1 | 1994 | 581 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1994 | 484 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1996 | 643 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1996 | 2662 | 0.000 |
Why?
|